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Mammalian target of rapamycinMacroautophagy (autophagy) is an important factor affecting the function of vascular endothelial cells (VECs)
and must be tightly regulated in these cells. However, the precise mechanisms underlying this process,
particularly in the presence of serum, remain obscure. In this study,we identiﬁed trans-3,5,4′-trimethoxystilbene
(TMS) as a potent small molecule inducer of autophagy in human umbilical vascular endothelial cells (HUVECs)
in the presence of serum. Using high-throughput DNA microarray and siRNA transfection technologies, we
demonstrated that TMS induced autophagy by up-regulating the expression of the transient receptor potential
canonical channel 4 (TRPC4), an important cation channel in HUVECs. In addition, the overexpression of TRPC4
by plasmid transfection also induced autophagy. Mechanistic studies revealed that the up-regulation of TRPC4
increased the intracellular Ca2+ concentration, which, in turn, activated the Ca2+/CaMKKβ/AMPK pathway,
leading to mTOR inhibition and autophagy. Our study identiﬁes a novel role for TRPC4 in the regulation of
autophagy in VECs. TMS is a useful new tool for investigating the molecular mechanism of autophagy in VECs
and may serve as a potential lead compound for developing a class of autophagy inducers to treat autophagy-
related diseases.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Autophagy, or “self-eating,” is a bulk degradative process that is
evolutionarily conserved [1]. Autophagy is initiated by cellular stress
pathways, resulting in the sequestration or engulfment of cytosolic
proteins, membranes, and organelles in a double membrane vesicle
that fuses with endosomes and lysosomes, thereby delivering the
sequestered material for degradation [2]. Because autophagy plays a
critical role in cell growth, differentiation, development, and death,
the levels of autophagy must be properly regulated, and dysregulated
autophagy has been linked to many human pathophysiologies, such as
neurodegeneration, cancer, microbial infection, and cardiovascularrans-3,5,4′-trimethoxystilbene;
, transient receptor potential
almodulin-dependent protein
α subunit; mTOR, mammalian
VOs,acidicvesicularorganelles;
0S6K,70-kDaribosomalprotein
rotein 1;NO, nitric oxide; FGF-2,
enan University of Technology,
+ 86 371 67756513.diseases [2]. It is necessary to understand the details of the regulatory
processes of autophagy for therapeutic purposes [2]. However, the
molecular mechanisms of autophagy, particularly in mammalian cells,
are complex and remain poorly understood.
Vascular endothelial cells (VECs) comprise a single cell layer of
endothelium, forming the interior surface of blood vessels. VECs partic-
ipate inmany aspects of vascular biology andmaintain vascular homeo-
stasis [3]. Endothelial dysfunction is a signiﬁcant driving force of
cardiovascular diseases, such as atherosclerosis [4]. Previous studies
and our research have demonstrated that autophagy acts predominant-
ly as a prosurvival pathway in VECs to protect cells from stressful
conditions [5–7]. Recently, Torisu et al. [8] reported that autophagy
regulates endothelial vonWillebrand factor (vWF) secretion; therefore,
the inhibition of autophagy may be a useful strategy to prevent throm-
botic events, and manipulation of the autophagy signaling pathways in
VECs may be a novel therapeutic strategy to prevent or treat cardiovas-
cular diseases. Despite the increasing interest in autophagy, little is
known about the molecular mechanisms that regulate this process in
VECs.
The precise molecular mechanisms underlying autophagy are
restricted to speciﬁc tissues, cell types, and different conditions or
stresses. Inmany cell types, autophagy is strongly induced by starvation.
However, VECs are directly in contact with serum in vivo. In addition,
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cardiovascular diseases [9]. The identiﬁcation of small molecules to tar-
get autophagy in the presence of serum is a primary approach for the
development of novel autophagy regulators, which may also help us
understand the regulatory network of autophagy in VECs. `
Resveratrol (trans-3,5,4′-trihydroxystilbene; RES), a naturally
polyphenolic phytoalexin present in red wine and various plants, has
a variety of signiﬁcant physiological activities, including the induction
of autophagy in VECs [6,10]. Unfortunately, as an autophagy inducer of
VECs, its effect may be limited by the short half-life of this compound
in blood plasma [11]. In addition, RES has low oral adsorption and met-
abolic stability in humans because it has three hydroxyl groups [12].
Trans-3,5,4′-trimethoxystilbene (TMS), a naturally methylated deriva-
tive of resveratrol, has higher lipotropy and an extended half-life com-
pared with RES [12]. A number of studies have demonstrated that
TMS possesses anti-proliferative, anti-inﬂammatory, anti-invasive and
anti-angiogenic activities [13–16]. However, it has not been determined
whether TMS regulates autophagy.
In the present study, we found that TMS effectively induces autoph-
agy in VECs in the presence of serum. Using TMS as a tool, we identiﬁed
genes with increased expression when the cells were induced with
TMS, and we hypothesized that these genes may play vital roles in
regulating endothelial autophagy. We performed DNA microarrays on
cultured human umbilical VECs (HUVECs) stimulated with TMS and
identiﬁed 12 up-regulated genes and 6 down-regulated genes. The
transient receptor potential canonical channel 4 (TRPC4) was selected
for further study because it is the most highly induced gene and plays
important roles in the regulation of endothelial function, such as the
formation of endothelial tube [17], the integrity of cell–cell junctions,
and the endothelial barrier [18]. However, this gene's role in autophagy
has not been elucidated. The DNAmicroarray data led us to investigate
the role of TRPC4 in autophagy in VECs and the potential underlying
mechanism(s) of this activity.
2. Materials and methods
2.1. Cell culture and treatment
HUVECs were obtained in our laboratory as described [19]. The cells
were cultured on gelatin-coated plastic dishes in MCDB 131 medium
(Sigma-Aldrich, M8537) supplemented with 20% heat-inactivated
fetal bovine serum (FBS, HyClone, SV30087.02) and 70 ng/ml ﬁbroblast
growth factor 2 (FGF-2, GIBCO, 13256-029) in a humidiﬁed incubator at
37 °C with 5% CO2. The cells were used at or before passage 8. The iden-
tity of the HUVECswas conﬁrmed by their cobblestonemorphology and
strong positive immunoreactivity to CD31 (Santa Cruz Biotechnology,
sc-1506). The cells were treated with concentrations of TMS ranging
from 15 to 60 μM supplemented with 5% FBS for 1–6 h.
2.2. Acridine orange (AO) assay for acidic vesicular organelles (AVOs)
The volume of the AVOs was determined by staining with the
lysosomotropic agent AO (Sigma-Aldrich, 235474). After treatment,
the cellswere stainedwith AO (5 μg/ml) at 37 °C for 1min and observed
with ﬂuorescence microscopy (Nikon, Japan). The cytoplasm and
nucleus of the stained cells ﬂuoresced bright green, whereas the AVOs
ﬂuoresced bright red. The relative intensity of the red ﬂuorescence
was analyzed with the Image J software (NIH, USA).
2.3. Immunoﬂuorescence
HUVECs were ﬁxed in 4% paraformaldehyde (w/v) for 30 min at
room temperature and blocked in 1× PBS, 0.01% Triton X-100 (v/v),
and 5% goat serum (v/v). The cells were subsequently incubated with
anti-LC3B antibody (Sigma-Aldrich, L7543) overnight at 4 °C, and
the cells were incubated with normal IgG (Sigma-Aldrich, I5006) asnegative controls. Then the cells were incubated with Alexa Fluor 488
goat anti-rabbit IgG (Zhongshan Biological Technology, ZF-0311) for
1 h and evaluated with a laser scanning confocal microscope (Leica,
Germany). Different ﬁelds of view (N3 regions) were analyzed for
each labeling condition.
2.4. Western blot analysis
The primary antibodies against LC3B (L7543) and TRPC4
(SAB2102582) were purchased from Sigma-Aldrich. The primary anti-
body against SQSTM1 (610833) was purchased from BD Transduction
Laboratories. The primary antibodies against p-AMPKα (2531),
AMPKα (2532), p-mTOR (2971), mTOR (2972), p-p70S6K (9206),
p70S6K (9202), p-4EBP1 (9456), and 4EBP1 (9452) were purchased
from Cell Signaling Technology. The primary antibodies against
CaMKKβ (sc-100364) and β-actin (sc-47778) were purchased from
Santa Cruz Biotechnology. The secondary antibodies HRP-conjugated
anti-rabbit IgG (sc-2004) and anti-mouse IgG (sc-2371) were pur-
chased from Santa Cruz Biotechnology. After treatment, the cells were
lysed in lysis buffer containing 25 mM Tris–HCl (pH 6.8), 2% SDS, 6%
glycerol, 1% 2-mercaptoethanol, 2 mM PMSF, 0.02% bromophenol
blue, and a protease inhibitor cocktail (Sigma-Aldrich, P8340) for
10 min at room temperature and boiled for an additional 10 min. The
total endothelial protein extracts (30 μg) were separated by 12% or
15% SDS–polyacrylamide gel electrophoresis and transferred to a
polyvinylidene diﬂuoride (PVDF) membrane (Millipore, ISEQ09120).
The membrane was blocked with 5% (w/v) nonfat dry milk in PBS-
Tween 20 (PBST; 0.05%) for 1 h and then incubated with the primary
antibodies (1:10,000 in PBST) at 4 °C overnight. After three washes in
PBST, the PVDF membrane was incubated with the appropriate HRP-
conjugated secondary antibodies (1:20,000) for 1 h at room tempera-
ture. The immunoreactive bands were developed with either the
Pierce ECL (Thermo Fisher Scientiﬁc, 32106) western blotting system
or 3,3′-diamino-benzidine (DAB; Sigma-Aldrich, D8001). The relative
quantity of the proteins was analyzed with the Quantity One software
(Bio-Rad, Hercules, CA, USA).
2.5. Microarray experiment and analysis
Total RNA was extracted with TRIzol reagent (Invitrogen, 15596-
018) according to the manufacturer's instructions from the HUVECs
treated with DMSO or TMS (60 μM) for 1 h. The quality of the samples
was assessed by spectrophotometry (Nanodrop 2000, Thermo Fisher
Scientiﬁc, USA), and high-quality samples were transferred to the
Gene Tech (shanghai) Co., Ltd (http://www.genetech.com.cn/) for
labeling and hybridization to the Affymetrix Human GeneChip® Gene
1.0 ST Arrays according to the manufacturer's protocol. The microarray
data analysis was also performed by Gene Tech (shanghai) Co., Ltd.
Genes with Ntwofold changes and both the false discovery rate (FDR,
q) and the Wilcoxon rank-sum test signiﬁcance level (p) b0.05 were
considered signiﬁcantly regulated.
2.6. Semiquantitative RT-PCR
Total RNAwas prepared from the HUVECs using TRIzol reagent, and
2 μg RNA was reverse-transcribed with M-MLV reverse transcriptase
(Promega, M1705) according to the manufacturer's instructions.
The speciﬁc primers for TRPC4 were sense 5′-TCTGCAAATATCTCTGGG
AAGAATGC-3′ and antisense 5′-AAGCTTTGTTCGTGCAAATTTCCATTC-
3′, and for GAPDH, sense 5′-CTTTGGTATCGTGGAAGGACTC-3′ and
antisense 5′-TCTTCCTCTTGTGCTCTTGCTG-3′.
2.7. Quantitative real-time PCR (qRT-PCR)
The qRT-PCR reactions were performed with the Eppendorf PCR
System (Eppendorf AG, Hamburg, Germany). The level of TRPC4 was
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generated from serially diluted cDNA from a reference sample and nor-
malization to the level of GAPDH. The speciﬁc primer sequences for
TRPC4 and GAPDH are described above.
2.8. siRNA transfection
Both siRNAs against TRPC4 were previously described by Abdullaev
et al. [20] (TRPC4-1#, GGTCAGACTTGAACAGGCA; TRPC4-2#, GGCTCA
GTTCTATTACAAA). Cells at 80% conﬂuence were transfected with
siRNA with the RNAiFect Transfection Reagent (QIAGEN, 1022076).
After the cells were transfected for 48 h, the medium was replaced
with fresh MCDB 131 medium. The effect of gene silencing was moni-
tored by western blot analysis.
2.9. Plasmid transfection
The pCMV6-XL4-TRPC4 (SC114411) and pCMV6-XL4 plasmidswere
purchased from Origene Technologies. The cells were transfected with
pCMV6-XL4 or pCMV6-XL4-TRPC4 plasmid using the X-tremeGENE
HP DNA transfection reagent (Roche, 06 366 244 001) according to
the manufacturer's instructions. The medium was replaced after 6–8 h
incubation. Then the cells were cultured for 24 h. The transfection of
TRPC4 into the HUVECs was conﬁrmed by western blot analysis.
2.10. Determination of intracellular Ca2+ concentration
Intracellular Ca2+ concentrationmeasurements were obtained from
HUVECs preloaded with the Ca2+-sensitive ﬂuorescent dye Fluo3-AM
(Invitrogen, F-14218). Brieﬂy, the cells were loaded with 10 μM Fluo3-
AM and 0.02% Pluronic F127 (Invitrogen, P-6866) in basic MCDB 131
medium for 1 h at room temperature and then cultured for 30 min.
The Fluo3-AM was excited with an excitation wavelength of 488 nm,
and ﬂuorescence signals were collected at an emission wavelength of
543 nm using a laser scanning confocal microscope. The data were
analyzed with the Leica Confocal Software. The intracellular Ca2+ con-
centration was expressed as the intensity of ﬂuorescence relative to
that of the control at 0 h. For the detection of Ca2+ inﬂux, the cells
were treated with or without thapsigargin (TG, Sigma-Aldrich, T9033)
and constantly perfused throughout experiments with buffer contain-
ing 137 mM NaCl, 5.4 mM KCl, 10 mM HEPES, 10 mM glucose, and
1 mM MgCl2, pH 7.4 (nominally Ca2+-free) or supplemented with
2 mM CaCl2. The intracellular Ca2+ concentration was displayed as a
pseudo-ratio value of the actual ﬂuorescence intensity divided by the
average baseline ﬂuorescence intensity.
2.11. Statistical analyses
All experiments were performed in duplicate and repeated at least
three times. The data are expressed as the means ± standard error of
the mean (SEM). The differences between groups were analyzed by
one-way variance (ANOVA), and the means of two groups were com-
pared using Student's t-test with SPSS 17.0 (SPSS Inc., Chicago) version.
Differences were considered statistically signiﬁcant at p b 0.05.
3. Results
3.1. TMS induces mTOR-dependent autophagy in HUVECs
To determine whether TMS induces autophagy in HUVECs, we
ﬁrst performed AO staining. Cells in the control group displayed green
ﬂuorescence in the cytoplasm and nucleolus, but cells treated with 15,
30, or 60 μM TMS for 3 or 6 h displayed bright red ﬂuorescent dots
after AO staining, indicating that TMS induced the accumulation of
AVOs in the cytoplasm. Cells co-treated with the class III PtdIns3K
inhibitor 3-methyladenine (3-MA) and TMS (60 μM) showed a faintstaining pattern of red ﬂuorescent dots (Fig. 1A). To extend these
studies, immunoﬂuorescence was used to visualize the endogenous
LC3 puncta. The treatment of HUVECs with TMS (15, 30, or 60 μM) for
3 or 6 h signiﬁcantly increased the number and distribution of endoge-
nous LC3 puncta. Similar to the control group, cells displayed a diffuse
pattern of endogenous LC3 after 3-MA and TMS (60 μM) co-treatment
(Fig. 1B). Autophagy was further analyzed by evaluating the conversion
of LC3-I to LC3-II,which is a reliablemarker of autophagy. The treatment
of HUVECs with TMS (15, 30, or 60 μM) for 6 h resulted in robust LC3-II
accumulation in a dose-dependent manner, which was blocked by 3-
MA (Fig. 1C). Rapamycin was used as a positive control (Fig. 1A, B, C).
Transmission electron microscopy (TEM) analysis also showed an
increase in the double membrane-bound autophagosome structures in
TMS-treated HUVECs (Supplementary Fig. 1). Based on these results,
we propose that TMS induces autophagy in HUVECs.
Increased LC3-II levels and autophagosomes induced by TMS may
be related to either enhanced autophagosome formation because of
increased autophagic activity, or reduced autophagosome turnover
because of impaired autophagic ﬂux [21]. To discriminate between
the two possibilities, we evaluated the autophagic ﬂux in HUVECs.
p62 is involved in the formation of autophagosomes and is constitu-
tively degraded by the autophagic pathway through speciﬁc binding
to LC3 [22]. Therefore, a reduction in the amount of p62 reﬂects an in-
crease in autophagic ﬂux. TMS decreased the level of p62, which was
restored by 3-MA (Fig. 1C). This indicates that TMS does not impair
autophagic ﬂux. Additionally, if autophagy is induced by TMS, late-
stage autophagy inhibitors are expected to further increase the level
of LC3-II and the number of autophagosomes. Therefore, we utilized
the late-stage inhibitor of autophagy, baﬁlomycin A1, an inhibitor of
the vacuolar H+-ATPase, to suppress autophagic ﬂux. Our results
showed that HUVECs co-treated with TMS (60 μM) and baﬁlomycin
A1 showed amore signiﬁcant accumulation of LC3-II than cells treated
with TMS alone (Fig. 1D). Collectively, these data demonstrate that
TMS induces autophagy via initiation of autophagosome formation
in HUVECs. TMS can be used as a tool to evaluate endothelial autoph-
agy in cellular processes.
To investigate the molecular mechanism of TMS, we ﬁrst examined
its effects on the phosphorylation of the mammalian target of
rapamycin (mTOR), 70-kDa ribosomal protein S6 kinase (p70S6K),
and eukaryote initiation factor 4E binding protein 1 (4E-BP1) using
western blot analysis. One of the classical pathways that regulate the
formation of autophagosomes is controlled bymTOR [23]. mTOR activa-
tion enhances protein translation by phosphorylating its targets p70S6K
and 4E-BP1 and inhibits autophagy [9]. In the presence of serum,
autophagy is induced via mTOR-dependent or -independent pathways
in VECs [5,7,9,24–26]. Our results show that TMS (15, 30, or 60 μM)
decreases the phosphorylated levels of mTOR, p70S6K, and 4EBP1, sim-
ilar to rapamycin (Fig. 1E), suggesting that TMS induces autophagy in an
mTOR-dependent manner in the presence of serum.3.2. TRPC4 is essential for TMS-induced autophagy and inhibition of mTOR
in HUVECs
Next, we used TMSas a tool to identify novel regulators of autophagy
in VECs. HUVECs were stimulated with TMS (60 μM) in the presence of
serum for 1 h, and the RNA was isolated and its expression assessed
with Affymetrix DNA microarray chips. TMS highly up-regulated
TRPC4 (Table 1), and we conﬁrmed the results by PCR (Fig. 2A–D).
The gene changes were validated by determining the protein level
using western blot analysis (Fig. 2E, F).
It has been demonstrated that cultured HUVECs express TRPC pro-
teins, including isoforms of TRPC1 and 4 [17]. Here, we also detected
the effect of TMS on TRPC1 expression. TMS (60 μM) treatment did
not lead to an increase in TRPC1 expression both at gene and protein
levels in HUVECs (Supplementary Fig. 2).
Fig. 1. TMS induces mTOR-dependent autophagy in HUVECs. (A) Cells were treatedwith the indicated concentration of TMS or rapamycin (2 μM) for 3 or 6 h. 3-MA (5mM)was added to
theHUVECs for 1 h prior to TMS (60 μM) exposure. Theﬂuorescence graph shows that the accumulation of AVOs in the TMS-treated groups increased signiﬁcantly, whichwas inhibited by
3-MA. Magniﬁcation = 200. The bar graph shows the relative intensity of red ﬂuorescence per cell using the NIH Image J software. (B) After treatment (as described above), the cells
were stained the anti-LC3B antibodies for immunostaining. The immunoﬂuorescence graphs show an increase in endogenous punctate LC3, and the effect of TMS (60 μM) was inhibited
by 3-MA. Bar = 10 μm. The bar graph shows the quantiﬁcation of endogenous LC3 punctuate per cell. (C) After treatment for 6 h (as described above), the cell lysates were analyzed by
western blot using antibodies against LC3B or p62. 3-MA inhibited the effects of TMS (60 μM) on the accumulation of LC3-II and degradation of p62. (D) Cells were treatedwith orwithout
TMS (60 μM) for 6 h. Baﬁlomycin A (10 nM) was added to the cells for 1 h prior to TMS (60 μM) exposure. TMS induces a more signiﬁcant accumulation of LC3-II in the presence of
baﬁlomycin A1 than in cells treated with TMS alone. (E) The cells were treated with the indicated concentration of TMS or rapamycin for 6 h. TMS suppresses the phosphorylation of
mTOR, p70S6K and 4EBP1, similar to rapamycin. Rapamycin is the positive control. n= 3, *p b 0.05, **p b 0.01 vs. control, #p b 0.05, ##p b 0.01 vs. 60.
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we transfected HUVECs with TRPC4 siRNA or scrambled siRNA sepa-
rately for 48 h. The cells were then treated with TMS (60 μM) for 6 h.
Western blot analysis showed that 40 nm siRNA effectively suppressed
TRPC4 expression after treatment for 48 h (Fig. 3A, B). As shown in
Fig. 3A, TRPC4 siRNA transfection, but not scrambled siRNA, abrogatedTable 1
Eighteen genes with greater than 2-fold change in expression as demonstrated by the microar
Gene name Gene
Transient receptor potential cation channel 4 TRPC
Calcium/calmodulin-dependent protein kinase kinase 2, beta CaM
ERBB receptor feedback inhibitor 1 ERRF
Myelin protein zero-like 2 MPZ
Transmembrane protein 217 TME
RAB23, member RAS oncogene family RAB2
Sphingosine kinase 1 SPHK
microRNA 31 MIR3
GTP binding protein overexpressed in skeletal muscle GEM
Baculoviral IAP repeat-containing 3 BIRC
C2 calcium-dependent domain containing 4B C2CD
Heart and neural crest derivatives expressed 1 HAN
Cytochrome P450, family 1, subfamily B, polypeptide 1 CYP1
Cytochrome P450, family 1, subfamily A, polypeptide 1 CYP1
Thioredoxin interacting protein TXN
Olfactory receptor, family 4, subfamily F, member 17 OR4
G antigen 12 J GAG
Low-density lipoprotein receptor LDLRthe effect of TMS on increased LC3-II levels. To exclude the possibility
that TRPC4 siRNA promotes the fusion of autophagosomes with lyso-
somes, which rapidly degrade LC3-II, we used baﬁlomycin A1 to block
autophagosomal degradation. Western blot analysis of LC3B showed
that the accumulation of LC3-II induced by TMS increased signiﬁcantly
more in the control or scrambled siRNA-transfected cells than in theray analysis.
symbol RefSeq Fold change
4 NM_016179 10.10842
KKβ NM_006549 6.4927
I1 NM_018948 3.65693
L2 NM_144765 3.16604
M217 NM_145316 3.07513
3 NM_016277 2.60628
1 NM_182965 2.58502
1 NR_029505 2.27495
NM_005261 2.22736
3 NM_001165 2.1137
4B NM_001007595 2.10596
D1 NM_004821 2.0551
B1 NM_000104 −3.42825
A1 NM_000499 −3.06614
IP NM_006472 −2.27384
F17 NM_001005240 −2.18937
E12J NM_001098406 −2.13662
NM_000527 −2.05183
Fig. 2. TMS induces TRPC4 expression in HUVECs. (A and B) Semiquantitative RT-PCR (A) or quantitative RT-PCR (B) shows the TRPC4 mRNA expression in HUVECs after treatment with
TMS (60 μM) at the times indicated. (C and D) Semiquantitative RT-PCR (C) or quantitative RT-PCR (D) shows the TRPC4mRNA expression in HUVECs after treatment with the indicated
concentration of TMS for 1 h. (E)Western blot shows the TRPC4 protein expression inHUVECs after treatmentwith TMS (60 μM) at the times indicated. (F)Western blot shows the TRPC4
protein expression in HUVECs after treatment with the indicated concentration of TMS for 1 h. n= 3, *p b 0.05, **p b 0.01 vs. 0.
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was observed in the LC3-II levels between TRPC4 siRNA-transfected
cells treated with or without TMS in the presence of baﬁlomycin A1
(Fig. 3A, C), suggesting that depletion of TRPC4 inHUVECs effects the ac-
tivity of TMS. Moreover, TRPC4 depletion inhibited TMS-mediated p62
degradation compared to the control or scrambled siRNA-transfected
cells. When the lysosomal function was disrupted with baﬁlomycin
A1, cells treated with scrambled siRNA plus TMS had higher levels
of p62 than cells treated with TRPC4 siRNA plus TMS (Fig. 3A, D),
conﬁrming that knockdown of TRPC4 blocks TMS-induced autophagy
in HUVECs. Consistentwith this observation, TMS increased the number
of LC3 puncta in the control or scrambled siRNA-transfected cells,
whereas in the TRPC4-knockdown cells, the effect was completely
suppressed (Fig. 3E, F). Collectively, these results demonstrate that
TRPC4 plays an essential role in TMS-induced autophagy in HUVECs.
In the present study, we demonstrate that TMS promotes mTOR-
dependent autophagy. To elucidate the possible relationship between
TRPC4 and mTOR in TMS-induced autophagy, we determined whether
decreased TRPC4 expression affects mTOR activation. The HUVECs
were transfected with TRPC4 siRNA or scrambled siRNA and then
treated with TMS (60 μM) for 6 h. Western blot analysis showed that
transfection with the scrambled siRNA had no obvious effect on the
decrease of phospho (p)-mTOR caused by TMS. However, reduced
TRPC4 expression blocked the decrease of p-mTOR induced by TMS
(Fig. 3G, H, I). These data indicate that TRPC4 is required for the TMS-
induced inhibition of mTOR in HUVECs.3.3. TRPC4 overexpression is sufﬁcient to induce the autophagy and
inhibition of mTOR in HUVECs
In addition to the studies of TRPC4 depletion, we also
ascertained whether TRPC4 overexpression directly induces the au-
tophagy and inhibition of mTOR in VECs. For these experiments,
HUVECs were transiently transfected with either the pCMV6-XL4
(empty vector) or pCMV6-XL4-TRPC4 plasmid. Compared to the
control or empty vector-transfected cells, the HUVECs transfected
with pCMV6-XL4-TRPC4 showed signiﬁcantly higher levels of
TRPC4 (Fig. 4A). TRPC4 overexpression signiﬁcantly increased the
accumulation of LC3-II (Fig. 4A). LC3-II also accumulates when au-
tophagic ﬂux is impaired by pCMV6-XL4-TRPC4 transfection. To ex-
clude this possibility, we assessed the accumulation of LC3-II in the
presence of baﬁlomycin A1. Treatment HUVECs with pCMV6-XL4-
TRPC4 combined with baﬁlomycin A1 induced a more signiﬁcant
accumulation of LC3-II than cells treated with pCMV6-XL4-TRPC4
alone (Fig. 4A). Moreover, TRPC4 overexpression decreased the
levels of p62 in HUVECs. Cells transfected with pCMV6-XL4-TRPC4
showed higher levels of p62 compared to the cells transfected
with pCMV6-XL4 in the presence of baﬁlomycin A1 (Fig. 4A). There-
fore, TRPC4 overexpression increases autophagy in HUVECs. Trans-
fection of pCMV6-XL4-TRPC4, but not empty vector, consistently
increased the number of LC3 puncta in HUVECs (Fig. 4B). These
data demonstrate that TRPC4 is a novel regulator of autophagy in
VECs.
Fig. 3. TRPC4 is necessary for TMS-induced autophagy and mTOR inhibition in HUVECs. (A) Western blot analysis of TRPC4, LC3-I to LC3-II conversion, and p62 in HUVECs untransfected
or transfectedwith TRPC4 siRNA or scrambled siRNA for 48 h and then treated with or without TMS (60 μM) for 6 h. Baﬁlomycin A1was added to the cells for 1 h prior to TMS exposure.
The results demonstrate that knockdown of TRPC4 blocks TMS-induced autophagy in HUVECs. (B–D) The bar graphs show the relative levels of TRPC4 (B), LC3-II (C), and p62 (D). n=3,
*p b 0.05, **p b 0.01 vs. untreated group, #p b 0.05, TMS+ Baﬁlomycin A1 vs. TMS, TMS + Baﬁlomycin A1 + Scrambled siRNA vs. TMS+ Scrambled siRNA, $p b 0.05, $$p b 0.01, TMS +
TRPC4 siRNA-1# vs. TMS + Scrambled siRNA, TMS + TRPC4 siRNA-2# vs. TMS + Scrambled siRNA, &p b 0.05, TMS + Baﬁlomycin A1 + TRPC4 siRNA-1# vs. TMS + Baﬁlomycin A1 +
Scrambled siRNA, TMS + Baﬁlomycin A1 + TRPC4 siRNA-2# vs. TMS + Baﬁlomycin A1 + Scrambled siRNA. (E) The immunoﬂuorescence graphs show the endogenous LC3 punctuate
inHUVECs untransfected or transfectedwith TRPC4 siRNA or scrambled siRNA for 48 h and then treatedwith orwithout TMS (60 μM) for 6 h. Baﬁlomycin A1was added to the cells for 1 h
prior to TMS exposure. The results conﬁrm that TRPC4 is necessary for TMS-induced autophagy. Bar=10 μm. (F) The bar graph shows the quantiﬁcation of endogenous LC3 punctuate per
cell. n=3, **p b 0.01 vs. untreated group, #p b 0.05, TMS+ Baﬁlomycin A1 vs. TMS, TMS+ Baﬁlomycin A1+ Scrambled siRNA vs. TMS+ Scrambled siRNA, $p b 0.05, $$p b 0.01, TMS+
TRPC4 siRNA-1# vs. TMS+Scrambled siRNA, TMS+TRPC4 siRNA-2# vs. TMS+Scrambled siRNA, &p b 0.05, &&p b 0.01, TMS+Baﬁlomycin A1+TRPC4 siRNA-1# vs. TMS+Baﬁlomycin
A1 + Scrambled siRNA, TMS + Baﬁlomycin A1 + TRPC4 siRNA-2# vs. TMS + Baﬁlomycin A1 + Scrambled siRNA. (G) Western blot analysis of TRPC4 and p-mTOR in HUVECs
untransfected or transfectedwith TRPC4 siRNA or scrambled siRNA for 48 h then treatedwith or without TMS (60 μM) for 6 h. The results show that TRPC4 is necessary for TMS-induced
mTOR inhibition. (H and I) The bar graphs show the relative levels of TRPC4 (H) and p-mTOR (I). n= 3, *p b 0.05, **p b 0.01 vs. untreated group, #p b 0.05 vs. TMS + Scrambled siRNA.
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mTOR signaling. Our results show that TRPC4 overexpression
effectively prevents the phosphorylation of mTOR, similar to TMS
(Fig. 4C). Rapamycin, an inhibitor of mTOR signaling, whichsigniﬁcantly promotes autophagy in VECs, did not affect the level of
TRPC4 (Fig. 4D). Taken together, these results indicate that TRPC4
overexpression induces autophagy by suppressing downstream
mTOR signaling.
Fig. 4. TRPC4 overexpression directly induces autophagy andmTOR inhibition inHUVECs. (A)Western blot analysis of TRPC4, LC3-I to LC3-II conversion, and p62 inHUVECs untransfected
or transfected with pCMV6-XL4 (empty vector) or pCMV6-XL4-TRPC4 for 24 h. Baﬁlomycin A1 was added to the cells for 1 h prior to plasmid transfection. The results demonstrate that
TRPC4 overexpression induces autophagy in HUVECs. n= 3, *p b 0.05, **p b 0.01 vs. untreated group, #p b 0.05 vs. pCMV6-TRPC4. (B) The immunoﬂuorescence graphs show the endog-
enous LC3punctuate inHUVECs untransfected or transfectedwith pCMV6-XL4 or pCMV6-XL4-TRPC4 for 24h. Bar=10 μm. The bar graph shows thequantiﬁcation of the endogenous LC3
punctuate per cell. The results conﬁrm that TRPC4 overexpression induces autophagy in HUVECs. n=3, **p b 0.01 vs. Control. (C)Western blot analysis of TRPC4 and p-mTOR in HUVECs
untransfected or transfected with pCMV6-XL4 or pCMV6-XL4-TRPC4 for 24 h. TRPC4 overexpression signiﬁcantly suppresses phosphorylation of mTOR, similar to TMS. n= 3, *p b 0.05,
**p b 0.01 vs. Control. (D)Western blot analysis of p-mTOR, TRPC4, and LC3-I to LC3-II conversion inHUVECs treatedwith TMS (60 μM)or rapamycin for 6 h. Rapamycin does not affect the
expression of TRPC4, suggesting that TRPC4 may be upstream of mTOR signaling in autophagy induction. n= 3, *p b 0.05, **p b 0.01 vs. Control.
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AMPKα pathway, which leads to mTOR inhibition and autophagy in
HUVECs
TRPC4 is an important channel that may be involved in maintaining
intracellular Ca2+ in VECs [27]. Intracellular Ca2+ signaling is a critical
component of the canonical mTOR-dependent autophagy pathway
[28]. To gain mechanistic insight into TRPC4-regulated autophagy, we
examined the impact of TRPC4 on intracellular Ca2+ signaling in
HUVECs. We suppressed the expression of TRPC4 using siRNA and esti-
mated the intracellular Ca2+ concentration. Treatment of the control or
scrambled siRNA-transfected cells with TMS triggered a rapid andtransient increase in intracellular Ca2+within 30min, followed by a de-
crease similar to the level of the control or scrambled siRNA-transfected
cells. By contrast, for the scrambled siRNA-transfected cells, the increase
in intracellular Ca2+ induced by TMS was prevented in the TRPC4
knockdown cells, suggesting that TRPC4 is essential for the increase in
intracellular Ca2+ induced by TMS (Fig. 5A). Moreover, transfection of
pCMV6-XL4-TRPC4, but not empty vector, caused a rise in intracellular
Ca2+ concentration (Fig. 5B). These results suggested that TRPC4 is
involved in the increase in intracellular Ca2+.
Next, we investigated whether the increase in intracellular Ca2+
induced by TRPC4 up-regulation due to extracellular Ca2+ inﬂux. As
shown in Fig. 5C, Ca2+ inﬂux was not stimulated by Ca2+ addition in
Fig. 5.Up-regulation of TRPC4 by TMS or TRPC4 plasmid transfection increases intracellular Ca2+ concentration. (A) HUVECs were untransfected or transfected with TRPC4 siRNA or scram-
bled siRNA for 48 h and then treated with or without TMS (60 μM) for 0–360 min. Depletion of TRPC4 inhibits the TMS-induced elevation of intracellular Ca2+. (B) HUVECs were
untransfected or transfectedwith pCMV6-XL4 or pCMV6-XL4-TRPC4 for 0–2880min. The overexpression of TRPC4 increased intracellular Ca2+ comparedwith the empty vector-transfected
group. (C) HUVECs were untransfected or transfected with TRPC4 siRNA or scrambled siRNA for 48 h and then treated with or without TMS (60 μM) for 1 h. A change in extracellular Ca2+
concentration from0 to 2mM induced a rise in intracellular Ca2+ concentration in TMS-treated cells, whichwas abolished by transfection of TRPC4 siRNA. (D)HUVECswere untransfected or
transfected with pCMV6-XL4 or pCMV6-XL4-TRPC4 for 24 h. A change in extracellular Ca2+ concentration from 0 to 2mM induced a marked increase in intracellular Ca2+ concentration in
pCMV6-XL4-TRPC4 transfected cells compared with control or pCMV6-XL4 transfected cells. The line graphs indicated the ﬂuorescence intensity of Fluo-3. (E) HUVECs were treated as C. In
thepresence of PT, a change in extracellular Ca2+ concentration from0 to 2mM induced a rise in intracellular Ca2+ concentration in TMS-treated cells,whichwas abolished by transfection of
TRPC4 siRNA. (F) HUVECs were treated as D. In the presence of PT, a change in extracellular Ca2+ concentration from 0 to 2 mM induced an increase in intracellular Ca2+ concentration in
pCMV6-XL4-TRPC4 transfected cells compared with control or pCMV6-XL4 transfected cells. The line graphs indicated the ﬂuorescence intensity of Fluo-3.
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upon Ca2+ addition, whereas transfection with TRPC4 siRNA, but not
scrambled siRNA, blocked the increased intracellular Ca2+ induced byTMS. Similar results were obtained with TRPC4 plasmid transfection-
induced increased intracellular Ca2+ (Fig. 5D). To further demonstrate
whether the increased intracellular Ca2+ induced by TRPC4 up-
Fig. 6. TRPC4 up-regulation activates CaMKKβ-AMPKα axis by elevating intracellular Ca2+, which leads to mTOR inhibition and subsequent autophagy induction. (A) Western blot
analysis of p-mTOR and LC3-I to LC3-II conversion in HUVECs treatedwith or without TMS (60 μM) for 6 h or transfectedwith pCMV6-XL4 or pCMV6-XL4-TRPC4 for 24 h in the presence
or absence of BAPTA-AM (20 μM). Ca2+ chelation by BAPTA-AMprevents TMS or TRPC4 overexpression-inducedmTOR inhibition and autophagy. n=3, *p b 0.05, **p b 0.01 vs. untreated
group, #p b 0.05, ##p b 0.01, TMS + BAPTA-AM vs. TMS, pCMV6-TRPC4 + BAPTA-AM vs. pCMV6-TRPC4. (B) Western blot analysis of CaMKKβ and p-AMPKα in HUVECs untransfected
or transfected with TRPC4 siRNA or scrambled siRNA for 48 h and then treated with or without TMS (60 μM) for 6 h. Knockdown of TRPC4 prevents the up-regulation of CaMKKβ and
p-AMPKα induced by TMS. n = 3, **p b 0.01 vs. untreated group, #p b 0.05 vs. TMS. (C) Western blot analysis of CaMKKβ and p-AMPKα in HUVECs treated with or without TMS
(60 μM) for 6 h or transfected with pCMV6-XL4 or pCMV6-XL4-TRPC4 for 24 h in the presence or absence of BAPTA-AM. TRPC4 up-regulation activates CaMKKβ-AMPKα signaling by
increasing intracellular Ca2+. n= 3, **p b 0.01 vs. untreated group, #p b 0.05, ##p b 0.01, TMS + BAPTA-AM vs. TMS, pCMV6-TRPC4 + BAPTA-AM vs. pCMV6-TRPC4.
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with thapsigargin (TG), an endoplasmic reticulum Ca2+-ATPase inhibi-
tor. As shown in Fig. 5E, in the presence of TG, a restoration of extracel-
lular Ca2+ from 0 to 2 mM induced an expected rise in intracellular
Ca2+, which may due to store-operated Ca2+ entry (SOCE), and TMS
evoked an additional substantial increase in intracellular Ca2+ under
conditions where Ca2+ stores were already depleted. However, the
additional substantial increase in intracellular Ca2+ was blocked by
TRPC4 siRNA. Similar results were obtained with TRPC4 plasmid
transfection-induced increased intracellular Ca2+ (Fig. 5F). Collectively,
these data suggested that the increase in intracellular Ca2+-induced by
TRPC4 up-regulation is most likely originating from TRPC4-dependent
Ca2+ inﬂux.
BAPTA-AM, a chelator of intracellular Ca2+, prevented TMS or TRPC4
overexpression-induced mTOR inhibition and LC3-II accumulation
(Fig. 6A), indicating that the increase in intracellular Ca2+ is involved
in mTOR inhibition and autophagy induced by the up-regulation of
TRPC4.
Ca2+ entry via TRPC channels results in calcium/calmodulin-
dependent protein kinase kinase β (CaMKKβ) activation, which is re-
quired for phosphorylation of the downstream target AMP-activated
protein kinase α subunit (AMPKα) in VECs [27]. One of the major
downstream signaling pathways regulated by AMPKα is the mTOR
signaling pathway [28,29]. Additionally, microarray analysis showed
that CaMKKβ is up-regulated by TMS treatment (Table 1), indicating
that it may be involved in TMS-induced autophagy. Therefore, we hy-
pothesized that the up-regulation of TRPC4 induced by TMS or TRPC4
plasmid transfection increases intracellular Ca2+, which activates
CaMKKβ and AMPKα, leading to mTOR inhibition and autophagy in
VECs. To test this hypothesis, western blot analysis was used to analyze
the levels of CaMKKβ and p-AMPKα in HUVECs treated with scrambled
or TRPC4 siRNA in the presence or absence of TMS. Compared to the
control or scrambled siRNA-transfected cells, the levels of CaMKKβ
and p-AMPKα were signiﬁcantly elevated in the TMS-treated cells,
whereas knockdown of TRPC4 prevented the up-regulation of CaMKKβ
and p-AMPKα induced by TMS (Fig. 6B). Similar to TMS, TRPC4 overex-
pression was also highly effective in increasing the levels of CaMKKβand p-AMPKα (Fig. 6C). Treatment with BAPTA-AM blocked TMS
or pCMV6-XL4-TRPC4 transfection-induced CaMKKβ elevation and
AMPKα activation (Fig. 6C), suggesting that the up-regulation of
TRPC4 activates CaMKKβ-AMPKα signaling by increasing intracellular
Ca2+.
4. Discussion
In this study, we identiﬁed TMS, a naturallymethylated derivative of
resveratrol, as a potent inducer of autophagy in VECs in the presence of
serum. Using TMS as a tool, we identiﬁed newmolecules that contribute
to autophagy in VECs. We analyzed TMS-induced changes in the VEC
gene expression proﬁle using DNA microarrays, and found that TRPC4
was the most up-regulated gene after TMS treatments. Our results
suggest that TRPC4 may be involved in regulation of autophagy in
VECs. Of the TRP channels, TRPC4 channel is widely expressed in the
vasculature and has been suggested as a key determinant of endothelial
functions, such as endothelial permeability [30], nitric oxide (NO)-
dependent vasorelaxation [31], barrier stability [18], and endothelial
proliferation [20]. Despite these important functions, the role of TRPC4
in autophagy in VECs is unknown. We have shown that depletion of
TRPC4 inhibits TMS-induced autophagy. By contrast, TRPC4 overexpres-
sion is sufﬁcient to induce autophagy in HUVECs. The data presented
here extend the role of TRPC4 to a new ﬁeld, that of a regulator of
autophagy in VECs.
In the presence of serum, we demonstrated that TMS induces
autophagy in VECs in anmTOR-dependentmanner. One interesting ob-
servation is that similar to TMS treatment, TRPC4 plasmid transfection
directly inhibited mTOR, whereas knockdown of TRPC4 blocked mTOR
inhibition induced by TMS. Further studies revealed that the inhibition
of mTOR signaling by rapamycin did not affect the expression of
TRPC4. Therefore, TRPC4 is upstream of mTOR signaling during autoph-
agy induction.
Because of the prominent role of TRPC4 in endothelial Ca2+ signal-
ing, we next detected the effect of TRPC4 up-regulation on the intra-
cellular Ca2+ concentration. Our results showed that TMS increased
the intracellular Ca2+ concentration, whereas knockdown of TRPC4
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overexpression of TRPC4 by plasmid transfection also elevated the in-
tracellular Ca2+ concentration. It is surprising that enhanced expression
of TRPC4, which forms Ca2+ entry channels of very little constitutive
activity inmany cells, generates such profound elevation of intracellular
Ca2+. Based on fact that the contribution of TRPC4 proteins differ be-
tween cell types and particularly between VECs in different vascular
beds andmay depend on other environmental factors [32], it is possible
that the up-regulation of TRPC4 may directly or indirectly affect the
expression or activation of other proteins in HUVECs, which lead to
the increase in intracellular Ca2+. Additionally, we cannot exclude the
possibility that one or more serum components may activate TRPC4 in
HUVECs. These issues will need to be addressed in more detail in future
studies. Further experiments with extracellular Ca2+ loading revealed
that the increase in intracellular Ca2+-induced by TRPC4 up-
regulation, at least in part, due to Ca2+ inﬂux, rather than the release
of Ca2+ stores. The inhibition of Ca2+ signaling prevented TMS or
TRPC4 plasmid transfection-induced mTOR inhibition and autophagy,
suggesting that the up-regulation of TRPC4 increases the intracellular
Ca2+ concentration, which induces mTOR inhibition and autophagy in
VECs.
The mechanism by which TRPC4 negatively regulates mTOR signal-
ing via elevating intracellular Ca2+ was also determined in our study.
Based on previous studies, Ca2+ entry through TRPC4 channels causes
an increase in the level of intracellular Ca2+ in VECs. Ca2+ activates
CaMKKβ, which in turn phosphorylates AMPKα [28]. AMPKα is an up-
stream molecule of the mTOR signaling in the induction of autophagy
[33]. We observed that Ca2+ chelation by BAPTA-AM prevented the
TMS or TRPC4 plasmid transfection-induced increase of CaMKKβ and
p-AMPKα. Moreover, knockdown of CaMKKβ abrogated TMS-induced
AMPKα activation,mTOR inhibition and autophagy. Our results indicate
that CaMKKβ and AMPKα are required downstreamof TRPC4 and intra-
cellular Ca2+ signaling during autophagy induction in VECs.
Although more and more data link TRPC4 to speciﬁc VEC functions,
our report is the ﬁrst to identify a novel role for TRPC4 during the
regulation of autophagy. The mechanisms are most likely complex,
and multiple signaling pathways are potentially involved in this
process. Our results demonstrate that a major mechanism underlying
this process is the activation of the intracellular Ca2+/CaMKKβ/
AMPKα-mTOR signaling pathway in VECs. Nonetheless, many interest-
ing questions remain to be answered. For instance, it is uncertain which
splice variant of TRPC4 is up-regulated by TMS. Although the overex-
pression of TRPC4α variant in our experiments could induced autopha-
gy in HUVECs, the role of other TRPC4 variants in autophagy induction
cannot be excluded. Moreover, future studies are necessary to deter-
mine whether autophagy induced by TRPC4 up-regulation is protective
or detrimental for VECs and also to elucidate the mechanism by which
TRPC4 regulates autophagy under different conditions or in different
cell types. TMS is a useful tool to study themolecularmechanisms of au-
tophagy in VECs and is a potential lead compound for the development
of a class of autophagy promoters to treat autophagy-related cardiovas-
cular diseases.Acknowledgments
The authors thank Prof. Bo Zhou (State Key Laboratory of Applied
Organic Chemistry, Lanzhou University) for kindly providing TMS. This
study was ﬁnancially supported by the National Natural Science
Foundation of China (no. 31101001, 31100607, and 31471296), the
Key Project of Henan Educational Committee (no. 14A180028), the
Foundation for University Key Teacher by Henan Educational Commit-
tee (no. 2013GGJS-078), the Technological innovation incubator
program from Henan University of Technology (no. 11CXRC12),
and the doctoral scientiﬁc research start-up foundation from Henan
University of Technology (no. 2011BS013).Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.10.030.References
[1] Z. Yang, D.J. Klionsky, Eaten alive: a history of macroautophagy, Nat. Cell Biol. 12
(2010) 814–822.
[2] Y. Chen, D.J. Klionsky, The regulation of autophagy—unanswered questions, J. Cell
Sci. 124 (2011) 161–170.
[3] M.A. Gonzalez, A.P. Selwyn, Endothelial function, inﬂammation, and prognosis in
cardiovascular disease, Am. J. Med. 115 (Suppl. 8A) (2003) 99S–106S.
[4] P. Libby, Inﬂammation in atherosclerosis, Nature 420 (2002) 868–874.
[5] J. Han, X.Y. Pan, Y. Xu, Y. Xiao, Y. An, L. Tie, Y. Pan, X.J. Li, Curcumin induces autoph-
agy to protect vascular endothelial cell survival from oxidative stress damage,
Autophagy 8 (2012) 812–825.
[6] H. Guo, Y. Chen, L. Liao, W. Wu, Resveratrol protects HUVECs from oxidized-LDL
induced oxidative damage by autophagy upregulation via the AMPK/SIRT1 path-
way, Cardiovasc. Drugs Ther. 27 (2013) 189–198.
[7] L. Zhang, L. Cui, G. Zhou, H. Jing, Y. Guo, W. Sun, Pterostilbene, a natural small-
molecular compound, promotes cytoprotective macroautophagy in vascular
endothelial cells, J. Nutr. Biochem. 24 (2013) 903–911.
[8] T. Torisu, K. Torisu, I.H. Lee, J. Liu, D. Malide, C.A. Combs, X.S. Wu, I.I. Rovira, M.M.
Fergusson, R. Weigert, P.S. Connelly, M.P. Daniels, M. Komatsu, L. Cao, T. Finkel,
Autophagy regulates endothelial cell processing, maturation and secretion of von
Willebrand factor, Nat. Med. 19 (2013) 1281–1287.
[9] L. Wang, Z. Dong, B. Huang, B. Zhao, H. Wang, J. Zhao, H. Kung, S. Zhang, J. Miao,
Distinct patterns of autophagy evoked by two benzoxazine derivatives in vascular
endothelial cells, Autophagy 6 (2010) 1115–1124.
[10] Y. Takizawa, Y. Kosuge, H. Awaji, E. Tamura, A. Takai, T. Yanai, R. Yamamoto, K.
Kokame, T. Miyata, R. Nakata, H. Inoue, Up-regulation of endothelial nitric oxide
synthase (eNOS), silent mating type information regulation 2 homologue 1
(SIRT1) and autophagy-related genes by repeated treatments with resveratrol in
human umbilical vein endothelial cells, Br. J. Nutr. 110 (2013) 2150–2155.
[11] M. Asensi, L. Medina, A. Ortega, J. Carretero, M.C. Baño, E. Obrador, J.M. Estrela, Inhi-
bition of cancer growth by resveratrol is related to its low bioavailability, Free Radic.
Biol. Med. 33 (2002) 387–398.
[12] T. Walle, F. Hsieh, M.H. DeLegge, J.E. Oatis Jr., U.K. Walle, High absorption but very
low bioavailability of oral resveratrol in humans, Drug Metab. Dispos. 32 (2004)
1377–1382.
[13] G. Gao, X. Wang, X. Qin, X. Jiang, D. Xiang, L. Xie, J. Hu, J. Gao, Effects of
trimethoxystilbene on proliferation and apoptosis of pulmonary artery smooth
muscle cells, Cell Biochem. Biophys. 64 (2012) 101–106.
[14] M. Belleri, D. Ribatti, S. Nicoli, F. Cotelli, L. Forti, V. Vannini, L.A. Stivala, M. Presta,
Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing
trans-resveratrol derivative 3,5,4′-trimethoxystilbene, Mol. Pharmacol. 67 (2005)
1451–1459.
[15] J.H. Tsai, L.S. Hsu, C.L. Lin, H.M. Hong, M.H. Pan, T.D. Way, W.J. Chen, 3,5,4′-
Trimethoxystilbene, a natural methoxylated analog of resveratrol, inhibits breast
cancer cell invasiveness by downregulation of PI3K/Akt and Wnt/β-catenin signal-
ing cascades and reversal of epithelial-mesenchymal transition, Toxicol. Appl.
Pharmacol. 272 (2013) 746–756.
[16] Y.H. Deng, D. Alex, H.Q. Huang, N. Wang, N. Yu, Y.T. Wang, G.P. Leung, S.M. Lee, In-
hibition of TNF-α-mediated endothelial cell-monocyte cell adhesion and adhesion
molecules expression by the resveratrol derivative, trans-3,5,4′-trimethoxystilbene,
Phytother. Res. 25 (2011) 451–457.
[17] F. Antigny, N. Girardin,M. Frieden, Transient receptor potential canonical channels are
required for in vitro endothelial tube formation, J. Biol. Chem. 287 (2012) 5917–5927.
[18] A. Graziani, M. Poteser, W.M. Heupel, H. Schleifer, M. Krenn, D. Drenckhahn, C.
Romanin, W. Baumgartner, K. Groschner, Cell–cell contact formation governs
Ca2+ signaling by TRPC4 in the vascular endothelium: evidence for a regulatory
TRPC4-beta-catenin interaction, J. Biol. Chem. 285 (2010) 4213–4223.
[19] E.A. Jaffe, R.L. Nachman, C.G. Becker, C.R. Minick, Culture of human endothelial cells
derived from umbilical veins. Identiﬁcation by morphologic and immunologic
criteria, J. Clin. Invest. 52 (1973) 2745–2756.
[20] I.F. Abdullaev, J.M. Bisaillon, M. Potier, J.C. Gonzalez, R.K. Motiani, M. Trebak, Stim1
and Orai1 mediate CRAC currents and store-operated calcium entry important for
endothelial cell proliferation, Circ. Res. 103 (2008) 1289–1299.
[21] Y. Ragazzoni, M. Desideri, C. Gabellini, T. De Luca, S. Carradori, D. Secci, R. Nescatelli,
A. Candiloro, M. Condello, S. Meschini, D. Del Bufalo, D. Trisciuoglio, The thiazole de-
rivative CPTH6 impairs autophagy, Cell Death Dis. 4 (2013) e524.
[22] G. Bjørkøy, T. Lamark, A. Brech, H. Outzen, M. Perander, A. Overvatn, H. Stenmark, T.
Johansen, p62/SQSTM1 forms protein aggregates degraded by autophagy and has a
protective effect on huntingtin-induced cell death, J. Cell Biol. 171 (2005) 603–614.
[23] C.H. Jung, S.H. Ro, J. Cao, N.M. Otto, D.H. Kim, mTOR regulation of autophagy, FEBS
Lett. 584 (2010) 1287–1295.
[24] A. Csordas, S. Kreutmayer, C. Ploner, P.R. Braun, A. Karlas, A. Backovic, G. Wick, D.
Bernhard, Cigarette smoke extract induces prolonged endoplasmic reticulum stress
and autophagic cell death in human umbilical vein endothelial cells, Cardiovasc. Res.
92 (2011) 141–148.
[25] N. Meng, L. Wu, J. Gao, J. Zhao, L. Su, H. Su, S. Zhang, J. Miao, Lipopolysaccharide
induces autophagy through BIRC2 in human umbilical vein endothelial cells, J.
Cell. Physiol. 225 (2010) 174–179.
387L. Zhang et al. / Biochimica et Biophysica Acta 1853 (2015) 377–387[26] Q. Wang, B. Liang, N.A. Shirwany, M.H. Zou, 2-Deoxy-D-glucose treatment of
endothelial cells induces autophagy by reactive oxygen species-mediated activation
of the AMP-activated protein kinase, PLoS One 6 (2011) e17234.
[27] A.M. Bair, P.B. Thippegowda, M. Freichel, N. Cheng, R.D. Ye, S.M. Vogel, Y. Yu, V.
Flockerzi, A.B. Malik, C. Tiruppathi, Ca2+ entry via TRPC channels is necessary for
thrombin-induced NF-kappaB activation in endothelial cells through AMP-
activated protein kinase and protein kinase Cdelta, J. Biol. Chem. 284 (2009)
563–574.
[28] J.P. Decuypere, D. Kindt, T. Luyten, K. Welkenhuyzen, L. Missiaen, H. De Smedt, G.
Bultynck, J.B. Parys, mTOR-controlled autophagy requires intracellular Ca(2+)
signaling, PLoS One 8 (2013) e61020.
[29] J. Kim, M. Kundu, B. Viollet, K.L. Guan, AMPK andmTOR regulate autophagy through
direct phosphorylation of Ulk1, Nat. Cell Biol. 13 (2011) 132–141.[30] C. Tiruppathi, M. Freichel, S.M. Vogel, B.C. Paria, D. Mehta, V. Flockerzi, A.B. Malik,
Impairment of store-operated Ca2+ entry in TRPC4(−/−) mice interferes with
increase in lung microvascular permeability, Circ. Res. 91 (2002) 70–76.
[31] M. Freichel, S.H. Suh, A. Pfeifer, U. Schweig, C. Trost, P. Weissgerber, M. Biel, S.
Philipp, D. Freise, G. Droogmans, F. Hofmann, V. Flockerzi, B. Nilius, Lack of an endo-
thelial store-operated Ca2+ current impairs agonist-dependent vasorelaxation in
TRP4−/− mice, Nat. Cell Biol. 3 (2001) 121–127.
[32] M. Freichel, V. Tsvilovskyy, J.E. Camacho-Londoño, TRPC4- and TRPC4-containing
channels, Handb. Exp. Pharmacol. 222 (2014) 85–128.
[33] L. Zhang, H. Jing, L. Cui, H. Li, B. Zhou, G. Zhou, F. Dai, 3,4-Dimethoxystilbene, a
resveratrol derivative with anti-angiogenic effect, induces both macroautophagy
and apoptosis in endothelial cells, J. Cell. Biochem. 114 (2013) 697–707.
